Skip to main content
OpenTrials
Completed

NCT Number: NCT07346664

Medication Adherence and Lipid Management in Patients With Coronary Heart Disease After Percutaneous Coronary Intervention: Application of the Transitional Care Model

Patients with coronary heart disease (CHD) require long-term medication and lifestyle modification following percutaneous coronary intervention (PCI). However, they often face challenges such as poor medication adherence and inadequate self-management. This study aims to evaluate the effects of the transitional care model (TCM) on CHD patients after PCI, regarding medication adherence, self-efficacy, and lipid levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Transitional Care Model Behavior Cardiovascular Diseases Coronary Disease Coronary Heart Disease Health Behavior Heart Diseases Lipid Profile Medication Adherence Myocardial Ischemia Patient Acceptance of Health Care Patient Compliance Self-Efficacy Treatment Adherence and Compliance Vascular Diseases

Age range

47 year–58 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northern Jiangsu People's Hospital Affiliated to Yangzhou University

Yangzhou, Jiangsu, 225001, China

About this study

TCM improved medication adherence, self-efficacy, and lipid profiles in CHD patients after PCI, while enhancing overall patient satisfaction. Compared with routine nursing care, TCM yielded superior clinical benefits and is recommended for broader application in the post-PCI management of CHD patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients clinically diagnosed with CHD according to established diagnostic criteria
  • patients who met the World Health Organization (WHO) indications for PCI
  • complete clinical data available

Exclusion criteria

  • Patients with cognitive impairment
  • Patients with incomplete follow-up data.
  • Patients with comorbid malignancy
  • Patients with severe hepatic
  • Patients with renal insufficiency

Treatment and study plan

routine nursing care group

Other

Patients assigned to the control group underwent routine nursing care based on the standardized medical treatment, including admission health education (PCI postoperative risk management and medication instructions), psychological counseling, dietary and exercise guidance, individualized rehabilitation planning, and discharge instructions. After discharge, patients attended routine outpatient follow-up visits, including laboratory testing of blood lipids, blood pressure, and blood glucose, without structured follow-up or WeChat-based education. Routine outpatient education and guidance were provided only.

TCM intervention group

Other

Patients in the observation group received a 3-month TCM intervention delivered by specially trained nurses, in addition to routine nursing care.

Primary outcomes

  1. Medication Adherence

    Time frame: Baseline (before discharge) and 3 months after discharge

    Medication adherence will be assessed using the Medication Adherence Report Scale-5 (MARS-5). The scale consists of 5 items that evaluate nonadherent behaviors (e.g., forgetting to take medications, altering dosages). Each item is scored on a 5-point Likert scale (1="always" to 5="never"), with total scores ranging from 5 to 25. A higher total score indicates better medication adherence.

Secondary outcomes

  1. Self-efficacy

    Time frame: Baseline (before discharge) and 3 months after discharge

    Self-efficacy will be assessed using the General Self-Efficacy Scale (GSS). The GSS is a validated 16-item instrument, with each item scored from 0 to 4. Higher total scores reflect greater self-efficacy in managing health and adhering to treatment recommendations.

  2. Lipid Profile

    Time frame: Baseline (before discharge) and 3 months after discharge.

    Fasting serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) will be measured using an automated biochemical analyzer. All measurements will be performed in mmol/L.

Sponsors and collaborators

Lead sponsor

Qing Wang

Other

Registry information

Official study title

Northern Jiangsu People's Hospital Affiliated to Yangzhou University

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jan 16, 2026
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.